Please assess the completion status of the following clinical trial:

Trial Title: Cimzia Versus Mesalamine for Crohn's Recurrence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥18 years of age or older with Crohn's disease of any phenotype (luminal disease, perforating disease, stricturing disease) with an ileocolic distribution.~* Ileocolic Crohn's disease severe enough to require ileocolectomy (either open or laparoscopic).~Exclusion Criteria:~* Patients younger than 18 years of age, as there is little data on pediatric patients and since the Colorectal Surgery service only treats patients 18 years of age or older.~* Patients undergoing an ileocolectomy for any reason besides Crohn's disease.~* Patients requiring a stoma.~* Patients with short-bowel syndrome.~* Patients who are incarcerated, due to difficulties with frequent clinic visits given their incarceration and transportation issues.~* Patients who received previous anti-TNF therapy from infliximab or adalimumab within three months of surgery, or patients who have a history of a severe hypersensitivity reaction to infliximab or adalimumab~* Patients with a positive PPD and a suspicious finding on a chest x-ray suggestive of tuberculosis, or any patient with a history of tuberculosis.~* Patients who require postoperative therapy besides either mesalamine or certolizumab (steroids, antibiotics, and immunomodulator therapy would not be permitted starting at 4 weeks after ileocolectomy).~* Patients with significant psychiatric disorders (i.e. schizophrenia) and those with significant cognitive disorders, due to the difficulties with this patient group remaining compliant with frequent clinic visits, and due to the difficulty evaluating quality of life measures in these patients.~* Patients with a history of malignancy.~* Patients with a history of any demyelinating neurologic disease or a history of seizures.~* Patients with a history of severe congestive heart failure.~* Patients with a history of hepatitis B or C virus.~* Patients who are pregnant or who become pregnant.~* Involvement in any other clinical studies which use study medications.~* The subject has a condition, which, in the opinion of the investigator, would compromise the study or well-being of the subject or prevent the subject from meeting or performing the study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cimzia treatment arm (Type: EXPERIMENTAL): Beginning at 4 weeks after surgery, patients would be randomly assigned using a pulled card method to receive certolizumab at a dose of 400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks thereafter up to 12 months after enrollment.
- Mesalamine treatment arm (Type: ACTIVE_COMPARATOR): Beginning at 4 weeks after surgery, patients would be randomly assigned to receive mesalamine 800 mg orally three times daily for twelve months following enrollment.

Based on this trial design, predict the completion outcome and termination type (if applicable).